Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Neurology

Volumn 61, Issue 1, 2003, Pages 46-54

  Orgogozo, J M ^a,n   Gilman, S ^g   Dartigues, J F ^a   Laurent, B ^b   Puel, M ^c   Kirby, L C ^h   Jouanny, P ^d   Dubois, B ^e   Eisner, L ^j   Flitman, S ⁱ   Michel, B F ^f   Boada, M ^k   Frank, A ^l   Hock, C ^m  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c CHU PURPAN   (France)

^d HÔTEL DIEU   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h Pivotal Research Centers   (United States)

ⁱ 21st Century Neurology   (United States)

^j Baumel Eisner Neuromedical Inst   (United States)

^k ACE Foundation   (Spain)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

ⁿ HÔPITAL PELLEGRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; PLACEBO; QS 21;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MICROGLIA; MULTICENTER STUDY; ONSET AGE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; T LYMPHOCYTE; VACCINATION REACTION;

EID: 10744230547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000073623.84147.A8     Document Type: Article

References (34)

1. World Health Organization. Mental and neurological disorders, fact sheet no. 265. December 2001. Available at: http://www.who.int/inf-fs/en/fact265.html. Accessed October 21, 2002.
2. Fassbender K, Masters C, Beyreuther K. Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften 2001;88:261-267.
3. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-584.
4. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
5. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159:439-447.
6. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
7. Games D, Bard F, Grajeda H, et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42. Ann NY Acad Sci 2000;920:274-284.
8. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
9. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
10. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457.
11. Schenk D. Opinion. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-828.
12. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002;1:3.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002;298:1379.
16. Sriram S, Steinman L. Postinfectious and postvaccinial encephalomyelitis. Neurol Clin 1984;2:341-353.
17. Ada G. Vaccines and vaccinations. N Engl J Med 2001;345:1042-1053.
18. Hung KL, Liao HT, Tsai ML. The spectrum of postinfectious encephalomyelitis. Brain Dev 2001;23:42-45.
19. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001;56:1313-1318.
20. Tselis AC, Lisak RP. Acute disseminated encephalomyelitis. In: Antel J, Birnbaum G, Hartung HP, eds. Clinical neuroimmunology. Boston: Blackwell Science, 1998:116-147.
21. Walker RW, Gawler J. Serial cerebral CT abnormalities in relapsing acute disseminated encephalomyelitis. J Neurol Neurosurg Psychiatry 1989;52:1100-1102.
22. Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990;113:291-302.
23. Hollinger P, Sturzenegger M, Mathis J, Schroth G, Hess CW. Acute disseminated encephalomyelitis in adults: a reappraisal of clinical, CSF, EEG, and MRI findings. J Neurol 2002;249:320-329.
24. Caldemeyer KS, Smith RR, Harris TM, Edwards MK. MRI in acute disseminated encephalomyelitis. Neuroradiology 1994;36:216-220.
25. Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001;56:1308-1312.
26. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002;8:1270-1275.
27. Grubeck-Loebenstein B, Blasko I, Marx FK, Trieb I. Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci 2000;23:114.
28. Monsonego A, Zota V, Selkoe DJ. Immunogenic aspects of amyloid beta-peptide: implications for the pathogenesis and treatment of Alzheimer's disease. Neurobiol Aging 2002;23:S112.
29. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer's disease following immunization with amyloid beta peptide: a case report. Nat Med 2003;9:448-452.
30. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol 2001;20:737-744.
31. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002;59:398-407.
32. Mann DM, Iwatsubo T, Snowden JS. Atypical amyloid (Abeta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Acta Neuropathol (Berl) 1996;91:647-653.
33. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: Saunders, 1994:585-613.
34. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.